DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
1-Year Return
0.48%
This Quarter Return
+32.6%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$439M
AUM Growth
+$21.9M
(+5.3%)
Cap. Flow
-$52.3M
Cap. Flow
% of AUM
-11.9%
Top 10 Holdings %
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14
Top Buys
| 1 |
AtriCure
ATRC
|
$4.43M |
| 2 |
Perspective Therapeutics
CATX
|
$3.69M |
| 3 |
Insulet
PODD
|
$2.73M |
| 4 |
Larimar Therapeutics
LRMR
|
$2.52M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$2.44M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$15.2M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$5.74M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.25M |
| 5 |
SPDR S&P Biotech ETF
XBI
|
$5.01M |
Sector Composition
| 1 | Healthcare | 86.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Century Therapeutics
IPSC
$41.4M
| $5.46M | 1.24% |
1,307,407
| – | – |
|
|
27
Larimar Therapeutics
LRMR
$331M
| $4.98M | 1.13% |
656,373
+332,500
| +103% | +$2.52M |
|
28
Keros Therapeutics
KROS
$632M
| $4.49M | 1.02% |
67,754
-6,607
| -9% | -$437K |
|
29
Arcus Biosciences
RCUS
$1.23B
| $4.37M | 1% |
231,717
-1,000
| -0.4% | -$18.9K |
|
30
Galapagos
GLPG
$2.1B
| $4.19M | 0.95% |
130,175
| – | – |
|
|
31
Perspective Therapeutics
CATX
$263M
| $3.69M | 0.84% |
+310,364
| New | +$3.69M |
|
32
BioCryst Pharmaceuticals
BCRX
$1.74B
| $3.6M | 0.82% |
709,500
| – | – |
|
33
Astria Therapeutics
ATXS
$395M
| $3.14M | 0.72% |
223,265
-225,743
| -50% | -$3.18M |
|
|
RGLS
34
DELISTED
Regulus Therapeutics
RGLS
| $3.08M | 0.7% |
1,070,548
-40,501
| -4% | -$117K |
|
|
BCYC
35
Bicycle Therapeutics
BCYC
$483M
| $3.04M | 0.69% |
122,200
| – | – |
|
36
Accuray
ARAY
$170M
| $3.02M | 0.69% |
1,222,358
| – | – |
|
|
37
Insulet
PODD
$24.4B
| $2.73M | 0.62% |
+15,900
| New | +$2.73M |
|
38
Procept Biorobotics
PRCT
$2.13B
| $2.72M | 0.62% |
54,995
-8,305
| -13% | -$410K |
|
39
MediWound
MDWD
$182M
| $2.69M | 0.61% |
188,753
-68,900
| -27% | -$982K |
|
40
ARS Pharmaceuticals
SPRY
$1.06B
| $2.44M | 0.56% |
239,194
-71,975
| -23% | -$736K |
|
41
Aquestive Therapeutics
AQST
$612M
| $2.13M | 0.48% |
+500,000
| New | +$2.13M |
|
42
ProQR Therapeutics
PRQR
$252M
| $2.07M | 0.47% |
905,582
-35,000
| -4% | -$80.1K |
|
|
CMPS
43
Compass Pathways
CMPS
$489M
| $2.02M | 0.46% |
243,210
+50,210
| +26% | +$418K |
|
44
Lineage Cell Therapeutics
LCTX
$274M
| $2.02M | 0.46% |
+1,366,308
| New | +$2.02M |
|
45
Stoke Therapeutics
STOK
$1.08B
| $1.96M | 0.45% |
+145,000
| New | +$1.96M |
|
46
Sutro Biopharma
STRO
$86.5M
| $1.89M | 0.43% |
334,079
+51,000
| +18% | +$288K |
|
47
Inogen
INGN
$220M
| $1.68M | 0.38% |
208,790
+193,790
| +1,292% | +$1.56M |
|
48
Gossamer Bio
GOSS
$571M
| $1.66M | 0.38% |
1,409,262
-66,790
| -5% | -$78.8K |
|
|
BWAY
49
Brainsway
BWAY
$302M
| $1.57M | 0.36% |
297,655
-10,816
| -4% | -$57.2K |
|
50
BioNTech
BNTX
$24.9B
| $1.57M | 0.36% |
+17,000
| New | +$1.57M |
|